



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

BENNEKER et al.

Appl. No.: 09/200,743

Filed: November 30, 1998

For: CRYSTALLINE PAROXETINE  
METHANE SULFONATE (as amended)

Art Unit: 1625

Examiner: Chang, C.

Atty Docket POT-010US2

TECH CENTER 1600/2900

AUG 30 2001

RECEIVED

#23  
JLP  
9/19/01

**REQUEST FOR CLARIFICATION OF SUSPENSION LETTER**

Assistant Commissioner for Patents  
Washington, DC 20231

August 28, 2001

Sir:


In response to the office letter dated August 2nd, 2001, applicants request clarification of the reason for suspension of action under 37 C. F. R. 1.103.

Specifically, the present application has been suspended due to a potential interference. (See page 2 of the office letter). However, the cover sheet of the office letter indicates that the suspension was "requested" (presumably by applicants) and that the suspension will terminate six months from the date the "request" was "filed." Applicants have not requested suspension of examination in this application, nor has any request for suspension been "filed." Instead, this application has been suspended solely on the initiative of the USPTO under 37 C.F.R. 1.103(e).

Accordingly, applicants request written clarification that the suspension invoked in the present application was not requested by the applicants and is instead an action imposed by the USPTO under 37 CFR 1.103(e).

Should the Examiner have any questions regarding this application, she is encouraged to contact applicants' undersigned representative at telephone No. 703 753 8791.

Respectfully submitted,



---

Mark R. Buscher  
Registration No. 35,006  
Phone: (703) 753-8791  
Fax: (703) 753-8891

Synthon Pharmaceuticals, Ltd.  
P.O. Box 161  
Catharpin, VA 20143